A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer: The VIOLETTA Trial

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age50+
SponsorChinese University of Hong Kong

About this trial

This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

ISUP grade group 2 or 3 PCa

Systematic biopsies showing grade group 1-3 PCa just next to the MRI lesion is allowed

Systematic biopsies showing grade group 1 PCa far away from the lesion is allowed

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

  • Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation

    Device

    Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism.

Treatment groups

110 Participants
are divided into 1 treatment group
Group A: Targeted Microwave Ablation (TMA)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The oncological control of prostate cancer

Any clinically significant PCa (csPCa) detected on biopsy of treated area(s) per patient at 12 months after treatment, defined by: • ISUP grade group 2 or above PCa

Time frame
At 12 months after treatment

Secondary outcomes

1

Clinically significant cancer detection on biopsy of each ablated MRI visible lesion

Per-lesion analysis of csPCa detected on biopsy of any ablated areas at 12 months

Time frame
At 12 months after treatment
2

Cancer detection on biopsy of each ablated MRI invisible lesion

Per-lesion analysis of any cancer detected on biopsy of any ablated areas at 12 months

Time frame
At 12 months after treatment
3

Out-of-field recurrence: Any cancer outside treated area on systematic biopsy

Out-of-field recurrence: Any cancer outside treated area on systematic biopsy

Time frame
At 12 months after treatment
4

Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Complications of treatment using Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Time frame
At 3 Month, 6 Month and 12 Month

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chinese University of Hong Kong

Lead sponsor

Princess Margaret Hospital, Hong Kong

Collaborator

Siriraj Hospital

Collaborator

Universiti Putra Malaysia

Collaborator

Chinese General Hospital and Medical Center, Philippines

Collaborator